Starpharma Holdings Ltd (OTCQX International:SPHRY)

4.15
Delayed Data
As of Apr 17
 +0.173 / +4.35%
Today’s Change
3.27
Today|||52-Week Range
8.15
-1.67%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$132.4M

Company Description

Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. Starpharma has three core development programs: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Melbourne, Australia.

Contact Information

Starpharma Holdings Ltd.
Baker IDI Building
Melbourne Victoria (vic) 3004
P:(138) 532-2700
Investor Relations:

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Jacinth K. FairleyChief Executive Officer & Executive Director
Nigel J. BaadeChief Financial Officer & Secretary
David J. OwenVice President-Research
C. Paul BarrettVice President-Business Development
Tony EglezosVice President-Business Development

To view my watchlist

Not a member yet?

Sign up now for a free account